Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | NQO2 | P16083 | 6/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9267952 | 0.79 | CA12 (0.53) | CA12CA9GRIN2DGRIN3BGRIN1 | |
| SCHEMBL6370054 | 0.78 | CA12 (0.49) | CA12CA9GRIN2DGRIN3BGRIN1 | |
| SCHEMBL27364123 | 0.75 | CA12 (0.50) | CA12CA9NQO2PDE7A | |
| SCHEMBL28427455 | 0.75 | CA12 (0.44) | CA12CA9NQO2CYP19A1GRIN2D | |
| SCHEMBL29496155 | 0.75 | CA12 (0.49) | CA12CA9EIF4A3 | |
| SCHEMBL30908307 | 0.73 | CYP19A1 (0.46) | CA12CA9NQO2CYP19A1 | |
| SCHEMBL4589419 | 0.71 | CA12 (0.53) | CA12CA9NQO2CYP19A1GRIN2D | |
| SCHEMBL17543476 | 0.71 | NQO2 (0.44) | CA12CA9NQO2CYP19A1PDE4A | |
| SCHEMBL2165918 | 0.70 | CA12 (0.60) | CA12CA9 | |
| SCHEMBL12559602 | 0.69 | CA12 (0.55) | CA12CA9GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050096278-A1 | Antibacterial agents | ELLSWORTH EDMUND L (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005026145-A2 | QUINOLONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096278-A1 | Antibacterial agents | MRPL21, FBL, SDHA | CA12 4142/4885CA9 2563/4885NQO2 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.